Skip to content
Arvinas logo
Search
Close
Arvinas logo
Search
Close

Publication Year: 2015

BRD4 Degradation by PROTACs® Represents a More Effective Therapeutic Strategy than BRD4 Inhibitors in DLBCL

ARV-330: An Androgen Receptor PROTAC® Degrader for Prostate Cancer

ARV-330: PROTAC® Androgen Receptor Degrader for Prostate Cancer

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

BRD4 Degraders Produce Long-Lasting Loss of BRD4 Protein and Robust Efficacy in Burkitt’s Lymphoma, Multiple Myeloma and Prostate Cancer Cells

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

Targeted Degradation of the Androgen Receptor in Prostate Cancer

Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
Menu
  • Careers
  • Privacy Policy
  • Terms of Use
Linkedin-in Twitter

© 2023 Arvinas. All rights reserved.

Arvinas logo
Search
Close
  • Our Science
    • PROTAC® Discovery Engine
    • Scientific Publications
    • Partnerships
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Research & Development
    • Pipeline
    • Androgen Receptor
    • Estrogen Receptor
    • Neuroscience
  • Careers & Culture
    • Open Positions
    • Life in New Haven
    • Our Values
    • Benefits
    • Giving Back
  • Patients
    • Patients with Breast Cancer
    • Patients with Prostate Cancer
    • Clinical Trials
    • Expanded Access Policy
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Menu
  • Contact Us
Linkedin-in Twitter
Skip to content